Selvita Expands its Proteomics Services Offer
Selvita has expanded its portfolio of protein chemistry services.
Analysis, production and purification of recombinant proteins remain the major activities of Selvita’s Protein Chemistry Laboratory. These projects require high expertise in the design of genetic constructs, determination and selection of the optimal expression conditions and finally production and purification of recombinant proteins with highest purity and biological activity.
“Being aware of the importance of the protein targets at every step of the preclinical drug discovery process, we place a great emphasis on the quality of our protein products. The highest purity and biological activity of the proteins, which we deliver to our customers, are our major objective and concern,” said Dr Justyna Stec-Niemczyk, Head of the Protein Chemistry Laboratory.
Due to the dynamic development of the Protein Chemistry Laboratory and constantly increasing portfolio of customers, Selvita is currently increasing its capabilities in terms of proteomic analyses. These analyses can be used for instance for biosimilar product characterization, which are currently of high interest to many biotechnology companies. Expansion of the service offer is possible due to the access to the extended range of the state of the art scientific equipment. This includes highly sophisticated mass spectrometers (e.g., MALDI-TOF MS microflex LT, LC/MS ESI/Apci Q-TOF plus, LC/MS/TSQ, LC/RAPID/MS/DAD/ESI/IT), additional ultra HPLC systems with the range of the specialized detectors (e.g. UV-VIS, RI, DAD, ELSD, Corona CAD, MALS, DLS, FLD); and microscale thermophoresis measurement devices (Nanotemper Monolith NT).
Selvita’s protein chemistry offer, in addition to already available services such as, protein assays and PAGE patterns, LC services, N-terminal protein sequencing and amino acid analyses, CD spectra analyses and the crystallographic studies, now also includes
• Determination of intact mass of proteins including large proteins,
• Analysis of the posttranslational modifications,
• Determination of protein oligomeric state (quaternary structure) and aggregation
• Protein conformation stability
• Biophysical methods for the determination of various parameters of protein-protein and protein-ligand interactions.
Related News
-
News CPHI Podcast Series: The power of proteins in antibody drug development
In the latest episode of the CPHI Podcast Series, Lucy Chard is joined by Thomas Cornell from Abzena to discuss protein engineering for drug design and development. -
News Amgen sues Samsung biologics unit over biosimilar for bone disease
Samsung Bioepis, the biologics unit of Samsung, has been issued a lawsuit brought forth by Amgen over proposed biosimilars of Amgen’s bone drugs Prolia and Xgeva. -
News CPHI Podcast Series: Why we need to consider women in clinical trials
The latest episode of the CPHI Podcast Series with Lucy Chard covers women's health, specifically women's representation in clinical trials, the associated bias, and the impacts on health for this population. -
News US FDA does not approve MDMA therapy for PTSD, requests more data
The MDMA-based therapeutic developed by Lykos Therapeutics, a California-based Public Benefit Corporation (PBC), has been reviewed and unapproved by the US FDA. The regulator has requested additional phase III trial data for further safety and efficacy... -
News Novartis and Viatris latest facing lawsuit over HeLa cell misuse
Global pharmaceutical companies Novartis and Viatris are the latest hit with a lawsuit claim pertaining to alleged misuse of the ‘HeLa’ cell line from the estate of woman whose cancerous tissue cells were taken without consent. -
News Sanofi invests billions into Frankfurt insulin production site
French pharmaceutical company Sanofi have announced an investment of EUR1.3 billion at their existing BioCampus site in Frankfurt am Main for the expansion of insulin production. -
News Novel oral Type 1 diabetes drug gains US FDA IND designation
A University of Alabama at Birmingham startup has gained FDA clearance for Investigational New Drug clinical trials for an oral Type 1 diabetes drug, a milestone for diabetes treatment. -
News A Day in the Life of a Vice President in R&D & Engineering
In the Day in the Life of Series, we've already had the chance to get to know a range of people in various roles in the pharma industry. In the latest interview we get a glimpse into the R&D side of things from Jennifer Sorrells, Vice Presiden...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance